Takeda and NY biotech Ovid ink rare drug development pact
Biotech | January 18, 2017
Takeda, pushing on with its R&D metamorphoses, has signed a research deal and collab with New York’s private biotech Ovid that will see the small company work on the Japanese pharma’s new candidate for a rare form of childhood epilepsy. The deal is a little different that the usual pact; instead of Takeda buying into a promising med from Ovid, it is Ovid who will help out on the Osaka-based company’s TAK-935, a selective CH24H inhibitor, in rare pediatric epilepsies.